药品名称VIDAZA
申请号050794产品号001
活性成分AZACITIDINE市场状态处方药
剂型或给药途径INJECTABLE;INTRAVENOUS, SUBCUTANEOUS规格100MG/VIAL
治疗等效代码AP参比药物
批准日期2004/05/19申请机构CELGENE CORP
化学类型New molecular entity (NME)审评分类Priority review drug
罕用药/孤儿药
与本品相关的专利信息(来自橙皮书Orange Book)
专利号专利过期日是否化合物专利是否产品专利专利用途代码专利下载
历史专利信息
与本品相关的市场独占权保护信息
独占权代码失效日期
历史市场独占权保护信息
ODE2011/05/19
与药品注册相关的信息
申请号修订号审批结论公开文档类型文档创建时间获取文档
050794029APLetter2016/08/24下载
050794029APLabel2016/09/07下载
050794028APLetter2015/12/18下载
050794028APLabel2015/12/24下载
050794026APLabel2014/01/13下载
050794026APLetter2014/01/14下载
050794024APLabel2012/12/21下载
050794023APLabel2012/01/25下载
050794023APLetter2012/01/27下载
050794020APLetter2011/08/22下载
050794020APLabel2011/08/24下载
050794016APLabel2011/08/24下载
050794016APLetter2011/08/22下载
050794011APLetter2008/08/22下载
050794011APLabel2008/08/26下载
050794010APLetter2008/02/25下载
050794005APLabel2007/02/02下载
050794001APLetter2005/07/08下载
050794000APLabel2004/05/19下载
050794000APLetter2004/05/26下载
050794000APReview2004/08/05下载
药品注册审批历史信息
申请号修订号审批结论审批日期审批内容
050794029AP2016/08/23Labeling Revision
050794028AP2015/12/17Labeling Revision
050794027AP2015/02/23Manufacturing Change or Addition
050794026AP2014/01/10Labeling Revision
050794025AP2013/05/06Manufacturing Change or Addition
050794024AP2012/12/19Manufacturing Change or Addition
050794023AP2012/01/24Labeling Revision
050794020AP2011/08/17Labeling Revision
050794016AP2011/08/17Labeling Revision
050794011AP2008/08/20Efficacy Supplement with Clinical Data to Support
050794010AP2008/02/22Manufacturing Change or Addition
050794005AP2007/01/26Efficacy Supplement with Clinical Data to Support
050794001AP2005/06/29Labeling Revision
050794000AP2004/05/19Approval